Regeneron seeks to edge Roche out of DME space

Share this article:
Eylea outduels Lucentis for physician mindshare, survey shows
Eylea outduels Lucentis for physician mindshare, survey shows

A year after its eye drug Lucentis landed the FDA's approval for diabetic macular edema, Roche's hold on this Eylea-free zone of the market may soon be ending. Regeneron, Eylea's manufacturer, said Tuesday that it expects to submit an NDA for this very same indication to the FDA this year, while its European marketing partner, Bayer, is on track to do the same abroad.

This would mean more than a me-too in the diabetic macular edema (DME) space. As noted by Forbes, Lucentis has a downside in that its label has a fatality warning. Eylea's does not, and that could give the Regeneron drug an edge if it too gets approved for use in DME.

It's not the first threat to Lucentis' hold on the eye market. The wet macular-degeneration drug saw immediate competition from off-label use of Genentech's Avastin, then from macular-degeneration newcomer Eylea.

DME is linked to blurry vision and even blindness, and estimates say it affects about 560,000 Americans.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...